Immunomic Therapeutics

1 follower


Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform.

Industries

Employees

11-50

Links

Org chart

Teri Heiland
Chief Scientific Officer
Frances Harrison
SVP, Regulatory Affairs
Cara Sholter
VP, Quality Assurance

Board & advisors

Yang-Gon Jin
Director
Dong Gun Kim
Chief Executive Officer
John H. Sampson
Scientific Advisory Board
E. Antonio Chiocca
Scientific Advisory Board
Mark Pardoll
Scientific Advisory Board
David A. Reardon
Scientific Advisor
Paul Nghiem
Scientific Advisor